格隆汇2月11日丨ST得润（维权）(002055.SZ)公布，基于战略规划及核心业务发展需要，公司拟引入顺 益亚太有限公司（简称"顺益亚太"或"投资人"）对控股子公司柏拉蒂电子（深圳）有限公司（简称"深 圳柏拉蒂"或"目标公司"）进行增资，投资人拟以现金方式合计出资人民币12,000万元（其中2,392.50万 元计入注册资本，9,607.50万元计入资本公积）；公司部分放弃优先认缴增资权，拟以现金方式出资人 民币8,300万元（其中1,654.81万元计入注册资本，6,645.19万元计入资本公积），增资资金来源于公司 自有资金；深圳柏拉蒂另一现有股东深圳市得柏智连科技合伙企业（有限合伙）（简称"得柏智连"）放 弃本次优先认缴增资权。本次交易完成后，深圳柏拉蒂的注册资本将由人民币1,196.25万元增加至人民 币5,243.56万元，新增注册资本人民币4,047.31万元；公司对深圳柏拉蒂的持股比例将从60%下降至 45.25%，深圳柏拉蒂不再纳入公司合并报表范围。 ...

致：香港交易及結算所有限公司 公司名稱: BFB Health Limited（於開曼群島註冊成立並於百慕達存續的有限公司） 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00205 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 100,000,000,000 | HKD | | 0.01 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | 0 | | | HKD | | 0 | | 本月底結存 | | 100,000,000,000 | HKD | | 0.01 HKD | | 1,000,000,000 | 本 ...

Group 1 - The core viewpoint of the news is that ST Derun (002055) is expected to report a significant reduction in losses for the fiscal year 2025, despite forecasting a net loss of between 25 million to 40 million yuan [2][3] - The company anticipates a net profit of 28 million to 40 million yuan after deducting non-recurring gains and losses, indicating an improvement in its main business operations focused on connector products [2][3] - The company has faced negative impacts on profits due to provisions for expected liabilities related to an administrative penalty from the China Securities Regulatory Commission and investor litigation matters [2] Group 2 - On January 30, 2026, ST Derun's stock closed at 5.88 yuan, reflecting a 1.55% increase with a turnover rate of 3.88% and a trading volume of 230,400 shares, amounting to a transaction value of 137 million yuan [1] - On the same day, the net inflow of main funds was 2.2051 million yuan, indicating active buying behavior, while retail investors experienced a net outflow of 838,600 yuan [2][3]

截至2026年1月29日收盘，ST得润(002055)报收于5.79元，下跌1.53%，换手率4.45%，成交量26.44万 手，成交额1.55亿元。 当日关注点 交易信息汇总 资金流向 1月29日主力资金净流出28.84万元；游资资金净流出751.43万元；散户资金净流入780.27万元。 公司公告汇总 2025年度业绩预告 深圳市得润电子股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为-4,000万元 至-2,500万元，扣除非经常性损益后的净利润为2,800万元至4,000万元。业绩较上年同期大幅减亏，主 要因主营业务健康发展、聚焦连接器业务、原控股子公司不再并表减少亏损影响。同时，公司因收到证 监会行政处罚事先告知书及投资者诉讼事项计提预计负债，对利润造成较大负面影响。本次业绩预告未 经审计，最终数据以2025年度报告为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自【交易信息汇总】：1月29日主力资金净流出28.84万元，游资资金净流出751.43万元，散户资 金净流入780.27万元。 来 ...

《2025年度业绩预告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月29日收盘，ST得润（002055）报收于5.79元，较前一交易日下跌1.53%，最新总市值为35 亿元。该股当日开盘5.86元，最高5.95元，最低5.73元，成交额达1.55亿元，换手率为4.45%。 近日，深圳市得润电子股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润 为-4,000万元至-2,500万元，扣除非经常性损益后的净利润为2,800万元至4,000万元。业绩较上年同期大 幅减亏，主要因主营业务健康发展、聚焦连接器业务、原控股子公司不再并表减少亏损影响。同时，公 司因收到证监会行政处罚事先告知书及投资者诉讼事项计提预计负债，对利润造成较大负面影响。本次 业绩预告未经审计，最终数据以2025年度报告为准。 最新公告列表 ...

Core Viewpoint - *ST Tianyu (300205.SZ) is expected to report a loss of between 275 million to 550 million yuan for 2025, with a non-recurring loss of 287 million to 359 million yuan, and operating revenue projected between 160 million to 173 million yuan [1] Financial Performance - The company continues to experience net profit losses attributable to shareholders, primarily due to being on the U.S. SDN sanctions list and facing delisting risk warnings [1] - Significant declines in product sales and revenue have been reported, leading to increased asset impairment losses year-on-year [1] Legal and Operational Challenges - Major litigation has resulted in increased provisions for expected liabilities [1] - The company has recognized asset impairment losses related to its liquidated subsidiary, Shenzhen Changyu Investment Partnership (Limited Partnership) [1]

Core Viewpoint - ST Derun (002055.SZ) expects a net profit attributable to shareholders of between -40 million yuan and -25 million yuan for 2025, with a net profit of 28 million to 40 million yuan after deducting non-recurring gains and losses, indicating a significant reduction in losses compared to the previous year [1] Group 1 - The company's business operations are developing healthily and orderly, focusing on its main business, strengthening internal management, increasing R&D investment, and expanding market reach, which has led to continuous growth in revenue and profitability [1] - The former subsidiary, Meta System S.p.A., will no longer be included in the company's consolidated financial statements by the end of 2024, significantly reducing the negative impact on the company's profit levels [1] - The company received a notice of administrative penalty from the Shenzhen Regulatory Bureau of the China Securities Regulatory Commission (CSRC) on December 31, 2025, and is facing lawsuits from investors following an investigation by the CSRC initiated on December 25, 2024, leading to significant uncertainty regarding potential compensation amounts [1]

Group 1 - The company formerly known as 财讯传媒集团有限公司 has officially changed its name to BFB Health Limited, with the Chinese stock abbreviation updated to BFB HEALTH, while the stock code remains unchanged [1] - BFB HEALTH will focus on the remote medical health management sector as a publicly listed company in Hong Kong [1] - The company plans to allocate 50% of its secondary market financing for AI upgrades in the health industry and new drug development, while the other 50% will be used for product iteration, brand building, and upgrading intelligent production lines [1] Group 2 - BFB HEALTH is a private enterprise based in Bozhou, Anhui Province, leveraging the region's rich traditional Chinese medicine resources and a well-established health industry cluster [1] - The company has evolved from a regional leader to a national remote medical service platform, achieving large-scale and standardized operations in remote medical services [1] - BFB HEALTH has developed a closed-loop model of "online diagnosis + health management + product services," aligning with the industry's development path of "Internet + healthcare" [1]

Core Viewpoint - *ST Weir (002058.SZ) expects a significant increase in net profit for the year 2025, driven by major asset sales and acquisitions that have positively impacted its financial performance [1] Financial Performance - The company anticipates a net profit attributable to shareholders of between 190 million to 220 million yuan for the year 2025 [1] - The net profit after deducting non-recurring gains and losses is expected to be between 8 million to 12 million yuan [1] Major Transactions - In May 2025, the company completed a significant asset sale, divesting its entire instrument and meter-related business, which led to a substantial increase in investment income [1] - The company acquired a 49% stake in Shanghai Ziyan Machinery Technology Co., Ltd., resulting in full ownership of the company [1] - In September 2025, the company completed a major asset purchase, acquiring a 51% stake in Shanghai Zhijiang New Materials Technology Co., Ltd. [1] Business Transformation - Following the aforementioned transactions, the company's primary business has shifted to aluminum-plastic film manufacturing and automotive fixture manufacturing [1] - The operating performance of the subsidiary Shanghai Zhijiang New Materials Technology Co., Ltd. is expected to show growth compared to the previous year, contributing positively to the company's overall performance [1]

相比美国Hims，BFBHEALTH多了品牌模块。拆解BFBHEALTH的战略布局，可以发现，BFBHEALTH实行"1+N"模式：旗 下拥有1个跨境购药平台一海享购，以及N个独立品牌（DYESOO、多燕瘦、寿春堂、美丽奇迹、爱森发、比比高等），全面 守护用户的健康与美。此举也构建了品牌壁垒，难以被单纯的产品销售企业复制，这也将助力其成为中国远程医疗健康管理的 领导者。 BFBHEALTH也将对中国医疗健康产业的升级产生影响。作为扎根于安徽亳州的民营企业上市公司，BFBHEALTH依托当 地产业优势，带动了中药材种植、深加工、物流配送等配套环节升级。公司的发展吸引了健康食品研发、智能设备制造等配套 企业落户亳州，完善了产业生态，带动"亳州品牌"走向世界，强化亳州中医药之都的影响力。同时，公司提供大量就业岗位， 增加地方税收，助推区域经济增长，实现企业发展与区域经济的协同共赢。 BFBHEALTH带来的红利最终将惠及广大用户。在服务体验优化上，技术迭代将让在线问诊更便捷、慢病管理更精准、远 程会诊更高效。还将让更多地区的用户享受到优质医疗资源，无论是县域地区，还是农村与偏远地区，用户无需长途奔波，即 可通过手机 ...